NCT06197217

Phase III Clinical Study Evaluating the Efficacy and Safety of WPV01 in Patients With Mild/Moderate COVID-19

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial Evaluating the Efficacy and Safety of WPV01 in Patients With Mild to Moderate COVID-19

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,350 (actual)
• Sponsor: Westlake Pharmaceuticals (Hangzhou) Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The study is a multicenter, randomized, double-blind, placebo-controlled efficacy, safety Phase III clinical trial designed to evaluate the efficacy and safety of WPV01 in patients with mild/moderate COVID-19.

Conditions

• Mild to Moderate COVID-19

Interventions

Type	Name	Description
DRUG	WPV01	Subjects in the WPV01 group will receive WPV01 600mg orally (200mg, 3 tablets per dose), 3 times daily (TID) for 15 consecutive treatments
DRUG	Placebo	Subjects in the Placebo group will receive WPV01 Placebo orally (3 tablets per dose), 3 times daily (TID) for 15 consecutive treatments

Timeline

• Start date: 2023-06-14
• Primary completion: 2023-08-21
• Completion: 2023-09-20
• First posted: 2024-01-09
• Last updated: 2024-06-12

Locations

1 site across 1 country: China

Regulatory

• FDA-regulated drug study